Caplacizumab

Caplacizumab
Monoclonal antibody
Type	Single domain antibody
Source	Humanized
Target	von Willebrand factor (VWF)
Clinical data
Trade names	Cablivi
Other names	ALX-0081
AHFS/Drugs.com	Monograph
MedlinePlus	a619030
License data	US DailyMed: Caplacizumab;
Routes of; administration	Intravenous; subcutaneous
ATC code	B01AX07 (WHO) ;
Identifiers
CAS Number	915810-67-2;
DrugBank	DB06081;
ChemSpider	none;
UNII	2R27AB6766;
KEGG	D11160;
Chemical and physical data
Formula	C1213H1891N357O380S10
Molar mass	27876.19 g·mol−1

Caplacizumab (INN; trade name Cablivi) is a bivalent Single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.[1][2]

This drug was developed by Ablynx NV.[3] On 31 August 2018 it was approved in the European Union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression".[4]

It is an anti-von Willebrand factor humanized immunoglobulin.[5] It acts by blocking platelet aggregation to reduce organ injury due to ischemia.[5] Results of the phase II TITAN trial have been reported.[5]

In February 2019, caplacizumab-yhdp (Cablivi, Ablynx NV) was approved in the United States for treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP). The drug is used in combination with plasma exchange and immunosuppressive therapy.[6][7]

References

Statement On A Nonproprietary Name Adopted By The USAN Council - Caplacizumab, American Medical Association.
World Health Organization (WHO) (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
A Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)
European Medicines Agency. "An overview of Cablivi and why it is authorised in the EU" (PDF). Retrieved 1 October 2018.
Immune Drug Tackles Microvascular Thrombosis Disorder. Feb 2016
"FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder". U.S. Food and Drug Administration (FDA). 6 February 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: CABLIVI". U.S. Food and Drug Administration (FDA). 11 February 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019. This article incorporates text from this source, which is in the public domain.

External links

"Caplacizumab". Drug Information Portal. U.S. National Library of Medicine.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Caplacizumab, American Medical Association.

[2] World Health Organization (WHO) (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).

[3] A Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)

[4] European Medicines Agency. "An overview of Cablivi and why it is authorised in the EU" (PDF). Retrieved 1 October 2018.

[Titan2016-5] Immune Drug Tackles Microvascular Thrombosis Disorder. Feb 2016

[6] "FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder". U.S. Food and Drug Administration (FDA). 6 February 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019. This article incorporates text from this source, which is in the public domain.

[7] "Drug Trials Snapshots: CABLIVI". U.S. Food and Drug Administration (FDA). 11 February 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019. This article incorporates text from this source, which is in the public domain.